Genmab A/S (NASDAQ:GMAB – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $50.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 81.88% from the stock’s current price.
GMAB has been the subject of a number of other research reports. Truist Financial boosted their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, June 4th. BTIG Research boosted their price target on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Finally, Royal Bank of Canada upgraded shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $49.50.
Check Out Our Latest Analysis on GMAB
Genmab A/S Stock Performance
Hedge Funds Weigh In On Genmab A/S
Several large investors have recently made changes to their positions in GMAB. DDD Partners LLC purchased a new stake in Genmab A/S during the 2nd quarter worth approximately $8,860,000. Capital International Investors grew its position in Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after purchasing an additional 315,355 shares during the last quarter. First Trust Advisors LP grew its position in Genmab A/S by 16.0% during the 4th quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock worth $40,440,000 after purchasing an additional 175,292 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Genmab A/S in the fourth quarter valued at about $4,875,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after acquiring an additional 145,689 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
- Five stocks we like better than Genmab A/S
- 3 Tickers Leading a Meme Stock Revival
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- How to buy stock: A step-by-step guide for beginners
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.